Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells

Tajima, Ken; Ohashi, Rina; Sekido, Yoshitaka; Hida, Toyoaki; Nara, Takeshi; Hashimoto, Muneaki; Iwakami, Shin‐ichiro; Minakata, Kenji; Yae, Toshifumi; Takahashi, Fumiyuki; Saya, Hideyuki; Takahashi, Kazuhisa

doi:10.1038/onc.2009.478

Cited by 40 publications

(34 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, a connection between HA and OPN has been described in various contexts. Overexpression of OPN induces HAS2 expression and ECM production, and enhances cell binding to HA in cancer cells (36)(37)(38). Conversely, it has been shown that OPN is a transcriptional target of HA-induced signaling and that the expression of both is correlated with migration of glioma cells (39,40).…”

Section: Discussionmentioning

confidence: 99%

Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization

Kuipers

Rieck

Gurevich

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

The extracellular matrix polysaccharide hyaluronan (HA) accumulates at sites of autoimmune inflammation, including white matter lesions in multiple sclerosis (MS), but its functional importance in pathogenesis is unclear. We have evaluated the impact of 4-methylumbelliferone (4-MU), an oral inhibitor of HA synthesis, on disease progression in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Treatment with 4-MU decreases the incidence of EAE, delays its onset, and reduces the severity of established disease. 4-MU inhibits the activation of autoreactive T cells and prevents their polarization toward a Th1 phenotype. Instead, 4-MU promotes polarization toward a Th2 phenotpye and induction of Foxp3+ regulatory T cells. Further, 4-MU hastens trafficking of T cells through secondary lymphoid organs, impairs the infiltration of T cells into the CNS parenchyma, and limits astrogliosis. Together, these data suggest that HA synthesis is necessary for disease progression in EAE and that treatment with 4-MU may be a potential therapeutic strategy in CNS autoimmunity. Considering that 4-MU is already a therapeutic, called hymecromone, that is approved to treat biliary spasm in humans, we propose that it could be repurposed to treat MS.

show abstract

Section: Discussionmentioning

confidence: 99%

Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization

Kuipers

Rieck

Gurevich

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…At least two potential mechanisms have been provided in solid tumors as well as in inflammatory disease and might be useful models for treatment of haematological neoplasias: (i) Decrease of treatment resistance and increase of apoptosis in mesothelioma cell lines was achieved by siRNA silencing of CD44 or using CD44-neutralizing antibodies [149]. (ii) Developed for treatment of inflammatory disease PF-03475952, a fully human IgG2 anti-CD44 monoclonal antibody, might demonstrate a novel agent also useful in cancer therapy.…”

Section: Experimental Antagonization and Drug Resistancementioning

confidence: 99%

CD44 in hematological neoplasias

2011

View full text Add to dashboard Cite

“…Moreover, recent in vitro studies have revealed that OPN plays a vital part in the multidrug resistance of mesothelioma cells [38], as well as in enhancement of adhesion, proliferation, and migration activities of mesothelioma cells [39]. However, the specific role of OPN in the pathogenesis of MPM still remains unclear.…”

Section: Opnmentioning

confidence: 98%

Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma

Liu

Jiao

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor of the pleura closely related to asbestos exposure. Rare as it is, the incidence of MPM is predicted to increase mainly as a result of a lengthy latency period from the initial asbestos exposure, making it a public health concern for the next decades. Moreover, the patients with MPM have an extremely poor prognosis due to its high resistance to conventional oncologic treatments and delayed diagnosis. Although the result of current therapeutic modalities based on patient features and clinical stages is very frustrating, great advances have been shown in the knowledge of molecular biology of MPM in recent years. This is accompanied by dozens of putative prognostic biomarkers that are actively involved in tumor biological activities. These prognostic candidates can offer us a new insight into the biological characteristics of MPM, contributing to development of individualized therapeutic strategies directed against oncogenesis and tumor progression. Thus, personalized approaches based on the molecular biology of the patient's tissue or body fluid will potentially improve the present disappointing outcome, bringing new hope for patients with MPM. This article reviews the principal and several novel biomarkers that can have an influence on prognosis, in the hope that they can provide us with a more profound understanding of the biology of this lethal disease.

show abstract

Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells

Cited by 40 publications

References 41 publications

Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization

Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization

CD44 in hematological neoplasias

Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma

Contact Info

Product

Resources

About